Evidence map›Paper›PMID 38710532›Full record

ArticleJournal of gynecologic oncology2024

Genetic analysis of cervical cancer with lymph node metastasis.

Hao He, Misi He, Qi Zhou, Ying Tang, Jing Wang, Xiuying Li, Dongling Zou

Abstract read
In one paragraph

Article in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Organoid technology in cervical cancer research.American journal of cancer research · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao He *Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0003-3790-0603
Misi He *Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0001-8469-7690
Qi ZhouDepartment of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0001-5673-4263
Ying TangDepartment of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0003-0428-1228
Jing WangDepartment of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0003-3968-2830
Xiuying LiDepartment of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0003-4194-0843
Dongling ZouDepartment of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.ORCID 0000-0001-9158-8783

Funding

Beijing Health Alliance Charitable Foundation BJHA-CRP-092Chongqing Health Commission 2023ZDXM029CSTC CSTB2023NSCQ-MSX1030Qujiang District Quzhou City Life Oasis Public Service Center 113WJMF 320.6750.2022-22-12
6 · The paper itself

Abstract

objectiveTo find out the differences in gene characteristics between cervical cancer patients with and without lymph node metastasis, and to provide reference for therapy.

methodsFrom January 2018 to June 2022, recurrent cervical cancer patients 39 cases with lymph node metastasis and 73 cases without lymph node metastasis underwent testing of 1,021 cancer-related genes by next-generation sequencing. Maftools software was used to analyze somatic single nucleotide/insertion-deletion variation mutation, co-occurring mutation, cosmic mutation characteristics, oncogenic signaling pathways.

resultsEP300 and FBXW7 were significantly enriched in lymph node-positive patients. Lymph node-positive patients with EP300 or FBXW7 mutations had lower overall survival (OS) after recurrence. Both lymph node-positive and -negative patients had plenty of co-occurring mutations but few mutually exclusive mutations. Lymph node-positive co-occurring mutation number ≥6 had lower OS, while lymph node-negative co-occurring mutation number ≥3 had lower OS after recurrence. The etiology of SBS3 was defects in DNA double strand break repair by homologous recombination, which exclusively exist in lymph node-positive patients. There was no difference in median tumor mutation burden (TMB) between positive and negative lymph nodes, but TMB was significantly associated with PIK3CA mutation.

conclusionThe somatic SNV/Indels of EP300 and FBXW7, SBS3 homologous recombination-mediated DNA repair defect were enriched in lymph node-positive patients. For lymph node-positive patients, EP300 or FBXW7 mutations predicted poor prognosis. No matter lymph node-positive or negative, more co-occurring mutation number predicted poor prognosis. PIK3CA mutation may account for the higher TMB and help identify patients who benefit from immunotherapy.

Indexed as

F-Box-WD Repeat-Containing Protein 7Lymphatic MetastasisMutationUterine Cervical NeoplasmsAdultAgedClass I Phosphatidylinositol 3-KinasesE1A-Associated p300 ProteinFemaleGenetic TestingHigh-Throughput Nucleotide SequencingHumansLymph NodesMiddle AgedNeoplasm Recurrence, LocalPrognosisClass I Phosphatidylinositol 3-KinasesE1A-Associated p300 ProteinF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanPIK3CA protein, humanCervical CancerGenetic ProfileLymph Node Metastasis

Identifiers

PMID38710532
PMCPMC11543258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.